Read More Pharma Industry News Scholar Rock keeps apitegromab FDA decision alive as Europe filing is reset Scholar Rock has removed Catalent Indiana from the U.S. apitegromab application while keeping its September 30 FDA decision date intact, but the manufacturing issue has forced a European filing withdrawal and resubmission. byVenkateshAugust 23, 2026